Cancer Stem Cell News Volume 3.48 | Dec 10 2014

Cancer Stem Cell News 3.48 December 10, 2014

Cancer Stem Cell News

     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CSCN on Twitter

‘Wound Response’ of Cancer Stem Cells May Explain Chemo-Resistance in Bladder Cancer
A novel mechanism – similar to how normal tissue stem cells respond to wounding – might explain why bladder cancer stem cells actively contribute to chemo-resistance after multiple cycles of chemotherapy drug treatment. Researchers report targeting this “wound response” of cancer stem cells can potentially provide a novel approach for therapeutic invention. [Press release from Baylor College of Medicine discussing online prepublication in Nature] Press Release | Abstract
NeuroCult™ for Brain Tumor Research - View Publications

PUBLICATIONS (Ranked by impact factor of the journal)
Peritoneal Milky Spots Serve as a Hypoxic Niche and Favor Gastric Cancer Stem/Progenitor Cell Peritoneal Dissemination through Hypoxia-Inducible Factor 1α
The authors investigated whether hypoxic peritoneal milky spots were an ideal cancer stem cell niche suitable for gastric cancer stem/progenitor cells (GCSPCs) engraftment. They also evaluated the mechanisms through which the hypoxia-inducible factor-1α-mediated hypoxic microenvironment regulated GCSPC fate. [Stem Cells] Full Article

SMURF1 Silencing Diminishes a CD44-High Cancer Stem Cell-Like Population in Head and Neck Squamous Cell Carcinoma
Two cancer stem cells-like populations, CD44high/BMI1high and CD44high/ALDHhigh, were enriched from head and neck squamous cell carcinoma cell lines and evaluated for the expression of SMURF1 by qRT-PCR, flow cytometry, and immunoblotting. [Mol Cancer] Abstract | Full Article

Anchorage-Dependent Multicellular Aggregate Formation Induces CD44 High Cancer Stem Cell-Like ATL Cells in an NF-κB- and Vimentin-Dependent Manner
Investigators demonstrate that adult T-cell leukemia/lymphoma (ATL) cells cultured on a layer of epithelial-like feeder cells form anchorage-dependent multicellular aggregates (MCAs) and that a fraction of MCA-forming ATL cells acquire CD44 high cancer stem cell-like phenotypes. [Cancer Lett] Abstract

Cell-Surface Vimentin (csVim): A Mislocalized Protein for Isolating csVimentin+ CD133 Novel Stem-Like Hepatocellular Carcinoma Cells Expressing EMT Markers
Scientists examined the potential of targeting csVim to isolate stem-like cancer cells with epithelial-mesenchymal transition (EMT) phenotype, by using a specific csVim-binding antibody, 84-1. Using this antibody, they purified the csVim positive, CD133-negative cell population from primary liver tumor cell suspensions and characterized for stem cell properties. [Int J Cancer] Abstract

Tenascin-C: A Novel Candidate Marker for Cancer Stem Cells in Glioblastoma Identified by Tissue Microarrays
Tenascin-C (TNC) protein has been identified as a potential marker for cancer stem cells (CSCs) in gliomas based on previous work. Scientists investigated the expression of TNC in tissue microarrays including 17 glioblastoma multiforme, 18 WHO grade III astrocytomas, 15 WHO grade II astrocytomas, four WHO gradeastrocytomas and seven normal brain tissue samples by immunohistochemical staining. [J Proteome Res] Abstract

Detection of Circulating Tumor Cell Subpopulations in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
Investigators assessed which non-hematopoietic cell types are identifiable and whether their numbers differ in pre- and postoperative blood samples. They observed cells showing stem cell-like features like CD133+/CK/CD45 and cells with both epithelial and stem cell-like features such as CD133+/CK+/CD45. [PLoS One]
Full Article

(-)-Epigallocatechin-3-Gallate Inhibits Nasopharyngeal Cancer Stem Cell Self-Renewal and Migration and Reverses the Epithelial-Mesenchymal Transition via NF-κB p65 Inactivation
Scientists investigated the self-renewal and migration inhibitory effects of epigallocatechin-3-gallate toward nasopharyngeal cancer stem cells and clarified its mechanism of activity. [Tumor Biol] Abstract

Experimental Research of Host Macrophage Canceration Induced by Glioma Stem Progenitor Cells
Human glioma stem/progenitor cells transfected with red fluorescent protein gene (SU3-RFP) were seeded inside the abdominal cavity of transgenic nude mice, of which all nucleated cells could express green fluorescent protein (GFP), forming a tumor model with a double‑color RFP/GFP fluorescent tracer.
[Mol Med Rep]
Abstract | Download Full Article

[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.

The Role of Cancer Stem Cells in Glioblastoma
The authors discuss the evolution of the cancer stem cell model of tumorigenesis and describe the specific role of cancer stem cells in the pathogenesis of glioblastoma and their molecular and microenvironmental characteristics. They also discuss recent clinical investigations into targeted therapies against cancer stem cells in the treatment of glioblastoma. [Neurosurg Focus] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Verastem Presents Data at the 2014 American Society of Hematology Annual Meeting
Verastem, Inc. announced oral and poster presentations at the 2014 American Society of Hematology (ASH) Annual Meeting. The data presented at ASH identified an important role of FAK in high risk B-ALL characterized by Ikaros mutation, and demonstrated compelling preclinical proof of concept with the FAK inhibitors VS-4718 and VS-6063. [Press release from Verastem, Inc. discussing research presented at the 2014 ASH Annual Meeting and Exposition, San Francisco] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration).
Request your free copy.

OncoMed Begins Patient Dosing in Phase II Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer
OncoMed Pharmaceuticals, Inc. announced that patient dosing has begun in the randomized, placebo-controlled Phase II portion of the company’s “PINNACLE” clinical trial of its anti-Notch2/3 cancer stem cell antibody, tarextumab (OMP-59R5), for the treatment of small cell lung cancer. [OncoMed Pharmaceuticals, Inc.]
Press Release

Cellectar Biosciences Granted Orphan Designation for I-131-CLR1404 for the Treatment of Multiple Myeloma
Cellectar Biosciences, Inc. announced that the U.S. Food and Drug Administration has granted Cellectar’s request for orphan drug designation of I-131-CLR1404 for the treatment of multiple myeloma, an incurable cancer of plasma cells. [Cellectar Biosciences, Inc.] Press Release

Paul G. Allen to Give $100 Million to Create Cell Science Institute
Philanthropist and entrepreneur Paul G. Allen announced a commitment of $100 million to create the Allen Institute for Cell Science in Seattle. Founded to investigate and model the complex living machinery of cells, the nonprofit Allen Institute for Cell Science and its inaugural project, the Allen Cell Observatory, will accelerate disease research around the world by creating and sharing reagents, data and dynamic, predictive models of cells. [Allen Institute for Cell Science] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Keystone Symposia – Integrating Metabolism & Tumor Biology
January 13-18, 2015
Vancouver, Canada

NEW Keystone Symposia – Epigenetics and Cancer
January 25-30, 2015
Keystone, United States

NEW Stem Cells in Drug Discovery
June 2-3, 2015
Cambridge, United Kingdom

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Postdoctoral Position – Cancer and Developmental Biology (University of California, Irvine)

NEW Postdoctoral Fellow – Stem Cells and Cancer (Tsinghua University)

NEW Postdoctoral Fellow – Brain Stem Cells and Cancer (University of California, San Francisco)

Postdoctoral Position – ER Stress and Cancer Biology (Baylor College of Medicine)

Postdoctoral Position – Pluripotent Stem Cell Biology and Cancer Research (Memorial Sloan-Kettering Cancer Center)

Principal Investigator – Cancer Biochemist (Wake Forest Baptist Medical Center)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Postdoctoral Fellow – Energy Metabolism and Nutrient Sensing in Cancer Development and Stem Cells (MD Anderson Cancer Center)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us